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Mutations in the ATP13A2 gene (PARK9, OMIM 610513) cause autosomal recessive, juvenile-onset Kufor-
Rakeb syndrome and early-onset parkinsonism. ATP13A2 is an uncharacterized protein belonging to the
P5-type ATPase subfamily that is predicted to regulate the membrane transport of cations. The physiological
function of ATP13A2 in the mammalian brain is poorly understood. Here, we demonstrate that ATP13A2 is
localized to intracellular acidic vesicular compartments in cultured neurons. In the human brain, ATP13A2
is localized to pyramidal neurons within the cerebral cortex and dopaminergic neurons of the substantia
nigra. ATP13A2 protein levels are increased in nigral dopaminergic and cortical pyramidal neurons of
Parkinson’s disease brains compared with normal control brains. ATP13A2 levels are increased in cortical
neurons bearing Lewy bodies (LBs) compared with neurons without LBs. Using short hairpin RNA-mediated
silencing or overexpression to explore the function of ATP13A2, we find that modulating the expression of
ATP13A2 reduces the neurite outgrowth of cultured midbrain dopaminergic neurons. We also find that silen-
cing of ATP13A2 expression in cortical neurons alters the kinetics of intracellular pH in response to cadmium
exposure. Furthermore, modulation of ATP13A2 expression leads to reduced intracellular calcium levels in
cortical neurons. Finally, we demonstrate that silencing of ATP13A2 expression induces mitochondrial frag-
mentation in neurons. Oppositely, overexpression of ATP13A2 delays cadmium-induced mitochondrial frag-
mentation in neurons consistent with a neuroprotective effect. Collectively, this study reveals a number of
intriguing neuronal phenotypes due to the loss- or gain-of-function of ATP13A2 that support a role for this
protein in regulating intracellular cation homeostasis and neuronal integrity.
INTRODUCTION
In recent years, a number of genes have been identified that
are associated with autosomal recessive forms of parkinson-
ism including parkin (PARK2), DJ-1 (PARK7), PINK1
(PARK6) and ATP13A2 (PARK9) (1–3). Mutations in the
ATP13A2 gene cause Kufor-Rakeb syndrome (KRS), a
juvenile-onset, autosomal recessive neurodegenerative dis-
order characterized by slowly progressive levodopa-respon-
sive parkinsonism together with additional features
including supranuclear palsy, pyramidal signs, dystonia
and dementia (4–7). Homozygous or compound heterozy-
gous mutations have been identified in KRS subjects that
produce frameshift or splicing variants that result in trun-
cated forms of ATP13A2, leading to a loss of function
(6,8,9). Numerous missense mutations have recently been
identified in subjects with early-onset parkinsonism or Par-
kinson’s disease (PD), suggesting that ATP13A2 mutations
may contribute to the development of both KRS and parkin-
sonism depending on the severity of the mutation (10–13).
Neuroimaging studies in KRS subjects with ATP13A2 muta-
tions reveal diffuse brain atrophy with evidence of impaired
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nigrostriatal dopaminergic function (10,14). Thus, ATP13A2
mutations result in the dysfunction and/or degeneration of
the nigrostriatal dopaminergic pathway in addition to other
neuronal populations. The definitive confirmation of neuro-
pathology associated with ATP13A2 mutations will await
the future post-mortem analyses of affected subjects. The
combination of levodopa-responsive parkinsonism and
impaired function of the nigrostriatal dopaminergic
pathway in KRS and parkinsonism subjects with ATP13A2
mutations supports the selective degeneration of nigrostriatal
dopaminergic neurons. Whether ATP13A2-linked neurode-
generation is associated with Lewy body (LB) pathology
that is characteristic of idiopathic PD is not yet known.
At present, little is understood about how ATP13A2 muta-
tions precipitate neurodegeneration in subjects with KRS
or parkinsonism.
Human ATP13A2 is an 1180 amino-acid protein belonging
to the P5 subfamily of transport ATPases containing 10 trans-
membrane domains (15). ATP13A2 is localized, at least in
part, to lysosomes where it may participate in the ATP-
dependent transport of cations across vesicular membranes
(6,8). However, at present, the cation-transporting activity of
ATP13A2 has not been directly demonstrated, and the cation
selectivity of this transporter is not known. In yeast, deletion
of ypk9, an ortholog of ATP13A2, confers sensitivity to
growth in the presence of heavy metals, including cadmium,
manganese, nickel and selenium, implicating ATP13A2 in
the transport or regulation of these metal cations (16,17). A
recent study suggests that the overexpression of
human ATP13A2 may regulate the intracellular concentration
of manganese in mammalian cells and protects from
manganese-induced cell death (18). ATP13A2 mRNA is
enriched in the mammalian brain where it is widely expressed
by many neuronal populations, especially substantia nigra
dopaminergic neurons (6,15). ATP13A2 mRNA expression
is dramatically up-regulated in surviving nigral dopaminergic
neurons of idiopathic PD brains, thus potentially supporting a
link between ATP13A2 and idiopathic PD (6). Furthermore,
ATP13A2 overexpression was recently shown to confer pro-
tection against a-synuclein-induced cytotoxicity in yeast,
worm and neuronal models (16). Therefore, ATP13A2 may
provide a link between environmental toxins (i.e. manganese)
and genetic factors that are implicated in the pathogenesis of
PD. At present, the physiological role of ATP13A2 in mam-
malian neurons is poorly understood and the mechanism
through which pathogenic mutations precipitate neuronal de-
generation is unclear.
Here, we explore the subcellular localization of ATP13A2
in rodent primary neurons and in human brains from normal
and PD subjects. Furthermore, we employ gene silencing or
overexpression of ATP13A2 in primary neuronal cultures to
model the loss- and gain-of-function effects of ATP13A2.
Our data demonstrate that ATP13A2 is normally localized to
intracellular acidic vesicular structures within neurons and is
up-regulated in neurons from affected regions of PD brains.
Furthermore, we demonstrate that ATP13A2 silencing or over-
expression regulates neuronal integrity, mitochondrial morph-
ology and intracellular cation flux. The implications of
our findings for ATP13A2-linked familial parkinsonism are
discussed.
RESULTS
Development of an ATP13A2-specific polyclonal antibody
To begin to explore the function of ATP13A2, we generated
an affinity-purified rabbit polyclonal antibody (named
LMNR1) raised against a synthetic peptide corresponding to
residues 499–511 (LRINLGGKLQLV) of the human
protein; a region that is highly conserved with the rat and
mouse sequence. This peptide is located within the second
intracellular loop of ATP13A2 immediately adjacent to the
P-domain phosphorylation motif (DKTGT, 513–517) (6).
LMNR1 antibody specifically detects full-length V5-tagged
human ATP13A2 and untagged mouse ATP13A2 transiently
expressed in HEK-293T cells by western blotting (Fig. 1A).
LMNR1 antibody also detects a major protein species in
soluble mouse brain extracts with a molecular mass of
130 kDa by western blotting, corresponding to the predicted
size of endogenous mouse ATP13A2 (Fig. 1B). This
130 kDa species is not detected following pre-absorption
of the antibody with an excess of peptide antigen (Fig. 1B).
To explore the subcellular localization of ATP13A2, we con-
ducted subcellular fractionation of mouse brain tissue.
ATP13A2 is enriched within the light membrane (P3, i.e.
microsomal) fraction containing lysosomes (LAMP1), Golgi
(Giantin) and endoplasmic reticulum (ER) (PDI), but is also
detectable albeit at lower levels in the heavy membrane (P2,
i.e. mitochondria and crude synaptosomes), synaptosomal
membrane (LP1) and synaptic vesicle-enriched (LP2) frac-
tions (Fig. 1C). Notably, ATP13A2 is generally absent from
soluble cytosolic fractions (S1, S3, LS1 and LS2), supporting
its subcellular localization as a transmembrane-spanning
protein. Collectively, our data demonstrate the specificity of
the LMNR1 antibody for detecting mammalian ATP13A2
and the enrichment of ATP13A2 within brain microsomal
fractions.
ATP13A2 localizes to intracellular acidic vesicular
compartments in neurons
Exogenously expressed human ATP13A2 has been shown to
localize, at least in part, to lysosomal membranes in mamma-
lian cell lines (6). To determine the subcellular localization of
ATP13A2 in neurons, we assessed the co-localization of ex-
ogenous ATP13A2 with subcellular markers in rat primary
cortical neurons by confocal fluorescence microscopy. Cor-
tical neurons were transfected with either V5-tagged human
ATP13A2 or green fluorescent protein (GFP)-tagged mouse
ATP13A2 alone or together with vesicular fusion proteins
(GFP-LC3, RFP-Rab5A, GFP-Rab7A or LAMP1-RFP) and
subjected to immunocytochemical analysis. Initially, our
ATP13A2 antibody (LMNR1) was not sufficiently sensitive
to detect endogenous ATP13A2 in cortical neurons by im-
munofluorescence (data not shown) but could detect exogen-
ously expressed mouse ATP13A2-GFP (Fig. 2A), which
localizes to vesicle membranes within the soma and processes
of cortical neurons (Fig. 2A). Exogenous human
ATP13A2-V5 adopts a distribution similar to ATP13A2-GFP
within the neuronal soma and proximal processes where it
co-localizes to a high degree with LAMP1-RFP, a marker of
lysosomal membranes, RFP-Rab5A, a marker of early
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endosomes, and GFP-Rab7A, a marker of late endosomes, but
to a smaller degree with the autophagosomal marker,
GFP-LC3 (Fig. 2A). Human ATP13A2-V5 also localizes
within neuronal processes where it associates closely
with markers of the microtubule network including
microtubule-associated protein 2 (MAP2; Fig. 2A) and bIII-
tubulin (Fig. 2B), suggesting localization of ATP13A2 to vesi-
cles undergoing transport. Mouse ATP13A2-GFP fails to
co-localize with the synaptic vesicle marker, synaptophysin-1
(Fig. 2B). Our data suggest that ATP13A2 is localized to a
number of acidic vesicular compartments within cortical
neurons, particularly lysosomes and endosomes.
ATP13A2 protein levels are increased in human
PD/dementia with Lewy body brains
To explore the expression of ATP13A2 in the human brain, we
conducted western blot analysis with our LMNR1 antibody on
detergent-soluble extracts derived from the striatum and
cerebral cortex (medial frontal gyrus) of human brains from
normal control subjects or subjects with PD and dementia
with Lewy bodies (DLB). ATP13A2 is detected in human
brain extracts as a major 130 kDa protein species
(Fig. 3A). Furthermore, ATP13A2 levels are markedly
increased in PD/DLB brains compared with normal control
brains (Fig. 3A and B). To evaluate the localization of
ATP13A2 in human brain, immunohistochemical analysis
was conducted on brain sections from control and PD subjects.
ATP13A2 localizes specifically to cytoplasmic punctate struc-
tures in pyramidal neurons located throughout the cingulate
cortex of control and PD subjects with an increase in immu-
noreactivity in PD brains (Supplementary Material, Fig. S1).
In the substantia nigra, ATP13A2 localizes selectively
within the cytoplasmic compartment of neuromelanin-positive
dopaminergic neurons, and we observe a marked increase of
ATP13A2 immunoreactivity in surviving dopaminergic
neurons of PD brains compared with control brains (Fig. 3C
and D). The increase of ATP13A2 immunoreactivity in
Figure 1. Development of an ATP13A2-specific antibody. (A) HEK-293T cells transiently expressing V5-tagged human ATP13A2 (left panel) or full-length
untagged mouse ATP13A2 (right panel) were probed with an antibody to ATP13A2 (LMNR1) to reveal a specific protein band of 130–150 kDa (arrows) in
transfected cells (+) that is absent from mock transfected cells (2). (B) Soluble protein extract from whole mouse brain was probed with ATP13A2-specific
antibody, LMNR1 (left panel). The LMNR1 antibody detects a major protein species of 130 kDa (indicated by arrows), corresponding to the expected mass of
endogenous ATP13A2. This protein species was not detected following pre-absorption of the LMNR1 antibody with an excess of peptide antigen (right panels).
(C) Subcellular fractionation of whole mouse brain tissue. ATP13A2 (LMNR1 antibody) is enriched in the light membrane (P3, microsomal) fraction, but also
detected in heavy (P2), synaptosomal (LP1), synaptic vesicle-enriched (LP2) membrane fractions. The distribution of marker proteins demonstrates the enrich-
ment of lysosomes (LAMP1; P3), mitochondria/heavy membranes (TIM23; P2 and LP1), ER (PDI; P2, P3, LP1 and LP2), Golgi (Giantin; P2 and P3) and synap-
tosomes/synaptic vesicles (synaptophysin 1; P2, P3, LP1 and LP2). Molecular mass markers are indicated in kilodaltons. Blots are representative of at least two
independent experiments.
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surviving dopaminergic neurons and cortical pyramidal
neurons of PD brains compared with control brains could be
confirmed using two additional antibodies to ATP13A2
(A9732, residues 1162–1180 and A3361, residues 804–821)
raised against distinct peptide epitopes (Supplementary Mater-
ial, Fig. S2). To determine whether ATP13A2 co-localizes
with LB pathology, confocal fluorescence microscopy was
conducted on cingulate cortex from DLB subjects using
antibodies to ATP13A2 (LMNR1) and phospho-serine-129
a-synuclein, a pathological species localized to the LB halo.
We do not observe direct co-localization of ATP13A2 with
LBs, but we do observe strong ATP13A2-positive cytoplasmic
punctate structures surrounding intracellular LBs (Fig. 3E).
Initial quantitation reveals that LB-positive neurons frequently
contained ATP13A2-positive puncta (70.8+ 4.2% of LB +
neurons). Furthermore, the intensity of ATP13A2-positive
Figure 2. Localization of exogenous ATP13A2 to intracellular acidic vesicles in cortical neurons. (A) Confocal fluorescence microscopy reveals the
co-localization of exogenous V5-tagged human ATP13A2 with GFP-LC3 (autophagosomes), RFP-Rab5A (early endosomes), GFP-Rab7A (late endosomes)
and LAMP1-RFP (lysosomes) in neuronal soma and processes. Exogenous GFP-tagged mouse ATP13A2 is specifically labeled by the ATP13A2 antibody
(LMNR1). (B) ATP13A2-V5 localizes to punctate structures located upon bIII-tubulin-positive neuronal processes, whereas ATP13A2-GFP fails to co-localize
with endogenous synaptophysin-1, a marker of synaptic vesicles. Cytofluorograms and correlation coefficients (Rcoloc) indicate the extent of co-localization
between exogenous ATP13A2 and each marker. Confocal images are representative of at least two independent cultures. Scale bar: 10 mm.
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immunofluorescence is significantly increased in LB-positive
neurons compared with LB-negative neurons, suggesting an
up-regulation of ATP13A2 levels in response to LB biogenesis
(Fig. 3F). Our data demonstrate that ATP13A2 protein is loca-
lized to neurons in the human brain where it is up-regulated in
affected brain regions of PD and DLB subjects.
Modulation of ATP13A2 expression compromises
dopaminergic neuronal integrity
Recessive mutations in ATP13A2 compromise the nigrostria-
tal dopaminergic pathway in subjects with KRS or early-onset
parkinsonism, which may reflect the degeneration of nigral
Figure 3. Increased levels of ATP13A2 in PD/DLB brains. (A) Soluble extracts derived from the striatum of normal control (nos 1–4) or PD/DLB (nos 1–5)
subjects probed with ATP13A2 antibody (LMNR1), and b-actin antibody as a control for protein loading. (B) Densitometric analysis of western blots revealing
increased levels of ATP13A2 in soluble extracts from striatum or medial frontal gyrus of PD/DLB subjects compared with normal control subjects. Data rep-
resent the mean+SEM levels of ATP13A2 normalized to b-actin and are expressed as a percent of control levels (n ¼ 4 for control or n ¼ 5 for PD/DLB
subjects). (C) Representative DAB immunostaining with ATP13A2 antibody (LMNR1) in the substantia nigra pars compacta from normal control or PD sub-
jects. Staining indicates ATP13A2 localized to characteristic neuromelanin-positive dopaminergic neurons. Scale bar: 100 mm (upper panel) or 20 mm (lower
panel). (D) Semi-quantitative analysis of DAB intensity corresponding to ATP13A2 levels in individual substantia nigra dopaminergic neurons from control or
PD subjects. Data represent the mean+SEM intensity of ATP13A2 staining in individual dopaminergic neurons (n ¼ 1449/control or 1257/PD neurons) taken
from at least three subjects per group. (E) Representative confocal fluorescent image of an intraneuronal LB from the cingulate cortex of a DLB subject (no. 8)
immunolabeled with phospho-S129-a-synuclein (paSyn, green) and ATP13A2 (LMNR1, red) antibodies. (F) Semi-quantitative analysis of ATP13A2 fluores-
cence intensity in cortical pyramidal neurons with (LB+, n ¼ 86 neurons) or without (LB2, n ¼ 2990 neurons) LBs. Data represent the mean+SEM fluor-
escence intensity of ATP13A2 in cortical pyramidal neurons from the cingulate cortex of a single DLB subject. ∗∗P , 0.001 analyzed by Student’s t-test.
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dopaminergic neurons (10,14). However, post-mortem neuro-
pathological data have not been reported from subjects with
ATP13A2 mutations in order to confirm dopaminergic neuron-
al loss. To directly explore the impact of ATP13A2 loss of
function on the viability and integrity of dopaminergic
neurons, we employed mir-30-adapted short hairpin RNA
(shRNA) constructs to silence the expression of endogenous
ATP13A2. To validate shRNA constructs, we demonstrate
by western blot analysis the successful knockdown of full-
length mouse ATP13A2 transiently expressed in HEK-293T
cells using shRNA constructs targeting rodent ATP13A2 but
not with a non-silencing control shRNA (Fig. 4A). We also
demonstrate the knockdown of endogenous ATP13A2 by
western blot analysis in cultured rat primary cortical neurons
using an ATP13A2-specific shRNA construct (Fig. 4B). To
explore the consequences of shRNA-mediated silencing of
endogenous ATP13A2 expression in neurons, we employed
rat primary midbrain cultures that typically consist of 6–8%
tyrosine hydroxylase (TH)-positive dopaminergic neurons
(data not shown). Midbrain cultures were co-transfected at
days-in-vitro (DIV) 3 with shRNA and GFP constructs at a
molar ratio of 10:1 to label transfected neurons, and cultures
were fixed at DIV 7 and immunostained with anti-TH antibody
to identify dopaminergic neurons (Fig. 4C). The number of
GFP-labeled dopaminergic neurons is similar following ex-
pression of control and ATP13A2-specific shRNAs, suggest-
ing that ATP13A2 knockdown does not induce overt
neuronal cell death (data not shown). We could confirm the
absence of neuronal cell death following shRNA-mediated si-
lencing of ATP13A2 using TUNEL labeling (data not shown).
However, silencing of ATP13A2 impairs neuronal integrity as
reflected by a marked reduction in the length of GFP-labeled
Figure 4. Modulation of ATP13A2 expression impairs neurite outgrowth of midbrain dopaminergic neurons. (A) Soluble extracts from HEK-293T cells tran-
siently co-expressing untagged mouse ATP13A2 and rodent-specific ATP13A2 (sh-ATP13A2) or non-silencing control (sh-control) shRNA plasmids were
probed with an antibody to ATP13A2 (LMNR1) to demonstrate shRNA-mediated knockdown of ATP13A2. b-tubulin indicates equivalent protein loading.
(B) Soluble extracts from rat primary cortical neurons transiently expressing control or ATP13A2-specific shRNAs, or untagged mouse ATP13A2, were
probed with antibodies to ATP13A2 (LMNR1) or b-tubulin as a control for protein loading. ATP13A2-specific shRNA reduces the levels of endogenous
ATP13A2 compared with control shRNA, whereas overexpression of mouse ATP13A2 is also detected. (C) Rat primary midbrain dopaminergic neurons
co-transfected at DIV 3 with shRNA (control or ATP13A2-specific) or V5-tagged human ATP13A2 (or control empty vector) and GFP plasmids at a 10:1
molar ratio. Cultures were fixed at DIV 7. Representative fluorescent micrographs reveal the co-labeling of dopaminergic neurons with GFP and TH for
each condition. Axonal processes are indicated by arrows. Scale bar: 100 mm. (D and E) Quantitative analysis of the length of GFP+/TH+ dopaminergic neur-
ites reveals a significant shortening of axonal processes due to (D) the shRNA-mediated silencing of ATP13A2 or (E) the overexpression of human ATP13A2,
compared with control neurons (sh-control or empty vector). Bars represent the mean+SEM length of TH+ neurites in micrometers (n ¼ 39–42 neurons for
shRNAs or n ¼ 28–39 neurons for hATP13A2) sampled across four independent cultures. Histograms indicate the mean frequency distribution of neurite length
for each condition (n ¼ 4 experiments). ∗P , 0.05 or ∗∗P , 0.01 compared with control plasmids assessed by unpaired Student’s t-test.
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dopaminergic neuritic processes compared with control
shRNA (Fig. 4C and D). The overexpression of ATP13A2
orthologs in yeast, worm and primary neuronal models was
previously shown to protect against a-synuclein-induced cell
death (16). To evaluate the potentially neuroprotective
effects of ATP13A2 overexpression, primary midbrain
neurons were co-transfected with V5-tagged human
ATP13A2 and GFP at a 10:1 molar ratio. Unexpectedly, over-
expression of human ATP13A2 induces a marked reduction in
neurite length of GFP-labeled dopaminergic neurons, similar
to the effects of ATP13A2 knockdown (Fig. 4C and E). To
assess whether the effects of ATP13A2 silencing are specific
to dopaminergic neurons, we transfected rat primary cortical
neurons with GIPZ plasmids co-expressing mir-30-adapted
shRNA and enhanced GFP (EGFP) at DIV 3, and the length
of GFP-positive neurites was assessed at DIV 7. Silencing of
ATP13A2 expression does not influence the length of MAP2-
positive cortical neurites compared with control shRNA
(Supplementary Material, Fig. S3). Furthermore, the shRNA-
mediated silencing of ATP13A2 does not promote apoptotic
cell death as revealed by TUNEL labeling of cortical
neurons (Supplementary Material, Fig. S3). Taken together,
our data suggest that ATP13A2 is involved in maintaining
the integrity of midbrain dopaminergic neurons. Our data
further suggest that ATP13A2 overexpression may comprom-
ise dopaminergic neuronal integrity and may not therefore
provide a promising neuroprotective strategy.
Modulation of ATP13A2 expression induces alterations
in autophagy
ATP13A2 co-localizes with intracellular acidic vesicular com-
partments in primary cortical neurons, particularly lysosomes
and endosomes and partially with autophagosomes. Autop-
hagy forms the major pathway for the transport of cytoplasmic
materials to lysosomes for their degradation and has been
implicated in neurodegenerative diseases, including PD (19–
23). To explore the potential relationship between ATP13A2
and the autophagy pathway, the effect of ATP13A2 silencing
and overexpression on autophagic activation was assessed.
Primary cortical neurons were co-transfected with shRNAs
or V5-tagged ATP13A2 and GFP-LC3 constructs at a 10:1
molar ratio followed by western blot analysis of neuronal
extracts. LC3 exists as a cytosolic form (LC3-I, 18 kDa) that
undergoes conversion to a membrane-associated form
(LC3-II, 16 kDa) localized specifically to autophagosomes.
The ratio of LC3-I and -II isoforms can be used to assess
the level of autophagic activation (24). ATP13A2 knockdown
or overexpression in cortical neurons fails to alter the ratio of
LC3-II to LC3-I, but instead leads to a marked decrease in the
steady-state levels of total GFP-LC3 (Fig. 5A and B). These
data suggest that modulating the expression of ATP13A2
does not influence autophagic activation, but may enhance
the turnover of GFP-LC3 most likely through lysosomal deg-
radation. Next, we explored the impact of ATP13A2 expres-
sion on GFP-LC3-positive autophagosomes in cortical
neurons by confocal microscopy. The overexpression of
human ATP13A2 produces a marked increase in the diameter
and number of GFP-LC3-positive puncta per neuron (Fig. 5C
and D), whereas silencing of ATP13A2 expression causes a
reduction in the diameter of GFP-LC3-positive puncta but
without a significant alteration in their number (Fig. 5E and
F). In general, however, ATP13A2 silencing or overexpression
results in fewer GFP-LC3-positive neurons with reduced fluor-
escence per neuron compared with control neurons (data not
shown) consistent with western blotting data (Fig. 5A and
B). Collectively, our data suggest that ATP13A2 modestly
regulates the number and size of autophagosomes.
ATP13A2 silencing modulates the kinetics of intracellular
pH in neurons
ATP13A2 is predicted to mediate the transport of heavy metal
cations, including cadmium, nickel, manganese and selenium,
since yeast cells with a deletion of the ykp9 gene (an ortholog
of ATP13A2) exhibit impaired growth in the presence of these
metals (16,17). However, the ability of ATP13A2 or Ykp9 to
transport cations has not yet been directly demonstrated. Since
ATP13A2 is localized predominantly to acidic vesicular com-
partments in neurons, we reasoned that modulation of
ATP13A2 expression may influence intracellular pH. Alter-
ation of intracellular pH also serves as an indirect measure
of cation transport. Primary cortical neurons were
co-transfected with V5-tagged human ATP13A2 and GFP
constructs at a 10:1 molar ratio to label transfected cells,
and intracellular pH was monitored in individual GFP-labeled
neurons by live-cell confocal microscopy using the ratiometric
fluorescent pH indicator, SNARF-1 (Fig. 6A–C). The overex-
pression of ATP13A2 fails to alter the basal intracellular pH of
neurons (Fig. 6C). Next, we monitored alterations in intracel-
lular pH in real time following acute exposure to 1 mM
cadmium (Fig. 6B). Cadmium induces a rapid intracellular
acidification measured over a period of 400 s in cortical
neurons, although overexpression of ATP13A2 does not influ-
ence the rate of acidification compared with control neurons
expressing GFP alone (Fig. 6B and C). Next, we assessed
the effects of ATP13A2 silencing on intracellular pH in cor-
tical neurons by co-transfecting cultures with shRNA and
GFP plasmids at a 10:1 ratio (Fig. 6D–F). Silencing of
ATP13A2 expression similarly fails to alter the basal intracel-
lular pH of neurons (Fig. 6F). ATP13A2 silencing does,
however, lead to an increased rate of acidification in response
to cadmium treatment compared with neurons expressing
control shRNA (Fig. 6E and F). Equivalent exposure to man-
ganese fails to elicit alterations in intracellular pH in cortical
neurons (data not shown), and it was not therefore possible
to assess the effects of ATP13A2 expression. Our data
suggest that ATP13A2 silencing modestly regulates the
kinetics of intracellular pH in neurons in response to
cadmium exposure rather than influencing basal pH, which
supports a role for ATP13A2 in regulating intracellular
cation transport. Furthermore, ATP13A2 may play a specific
role in regulating the transport of cadmium ions.
Modulation of ATP13A2 expression in neurons reduces
intracellular calcium levels
The regulation of intracellular pH by ATP13A2 most likely
reflects contributions from many cations in addition to H+
ions. A previous report demonstrated that overexpression of
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ATP13A4, a related member of the P5 ATPase subfamily,
caused an increase in intracellular calcium levels in COS-7
cells (25). Therefore, we decided to explore the effects of
modulating ATP13A2 expression on intracellular calcium
levels. Primary cortical neurons were co-transfected with
V5-tagged human ATP13A2 and DsRed2 constructs at a
10:1 molar ratio to label transfected cells, and intracellular
calcium levels were monitored in individual DsRed2-labeled
neurons by live-cell confocal microscopy using the fluorescent
calcium indicator, Fluo-4 (Fig. 7A–J). Overexpression of
ATP13A2 leads to a marked decrease in basal intracellular
calcium levels in cortical neurons compared with control
neurons expressing DsRed2 alone (Fig. 7A and B). We next
monitored alterations in intracellular calcium levels in real
time following acute exposure to 1 mM cadmium. Cadmium
induces a marked increase in intracellular calcium levels mea-
sured over 200 s in control neurons, whereas neurons overex-
pressing ATP13A2 display a smaller increase in calcium
levels (Fig. 7B and C). ATP13A2 overexpression does not
alter the rate or maximum levels of cadmium-induced
calcium release in cortical neurons (Fig. 7C–E). We also
assessed the effects of ATP13A2 silencing on intracellular
calcium release in cortical neurons (Fig. 7F–J). Similar to
ATP13A2 overexpression, ATP13A2 silencing reduces basal
and cadmium-induced intracellular calcium levels (Fig. 7F
and G), but does not influence the rate or maximum levels
of cadmium-induced calcium release (Fig. 7H–J). Our initial
experiments demonstrate that cadmium induces the release
of calcium from intracellular stores, rather than as a result of
increased extracellular calcium uptake (data not shown). Man-
ganese exposure fails to alter intracellular calcium levels in
neurons, and therefore, it was not possible to assess the
effects of ATP13A2 expression (data not shown). Our data
suggest that ATP13A2 regulates basal and cadmium-induced
intracellular calcium levels in neurons, thus further supporting
a role for ATP13A2 in regulating intracellular cation transport.
Figure 5. ATP13A2 modulates the size and number of LC3-positive autophagosomes in neurons. (A) Soluble extracts from rat primary cortical neurons
co-transfected with control or ATP13A2-specific shRNAs or V5-tagged human ATP13A2 and GFP-LC3 plasmids at a 10:1 molar ratio were probed with anti-
bodies to GFP to reveal LC3-I and LC3-II isoforms or b-tubulin as a control for protein loading. (B) Quantitative analysis of western blots revealing a normal
ratio of LC3-II to LC3-I (left), but reduced steady-state levels of total GFP-LC3 (right) due to ATP13A2 silencing or overexpression in cortical neurons. Bars
represent the mean+SEM (n ¼ 4 experiments). (C and E) Representative confocal fluorescent images indicating GFP-LC3-positive puncta in cortical neurons
following (C) overexpression of human ATP13A2 or (E) shRNA-mediated silencing of ATP13A2, compared with control plasmids (empty vector or control
shRNA). Scale bar: 5 mm. (D and F) Quantitative analysis of GFP-LC3-positive puncta indicates (D) the increased length and number of puncta due to
ATP13A2 overexpression or (F) the reduced length of puncta due to ATP13A2 silencing. Bars represent the mean+SEM length of puncta (micrometers) or
percent particles/cell compared with the control condition (n ¼ 9 neurons/condition from three experiments). Histograms indicate the mean frequency distribu-
tion of GFP-LC3-positive puncta length in micrometers for each condition (n ¼ 9 neurons/condition). ∗P , 0.05, ∗∗P, 0.01 or ∗∗∗P , 0.005 compared with
control assessed by unpaired Student’s t-test.
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Silencing of ATP13A2 expression induces mitochondrial
fragmentation in neurons
Mitochondria are important for buffering intracellular calcium
and for maintaining neuronal viability (26). Since manipulat-
ing ATP13A2 expression reduces intracellular calcium levels
and disrupts dopaminergic neuronal integrity, we assessed
the impact of modulating ATP13A2 expression on mitochon-
drial health. Mitochondria normally undergo dynamic cycles
of fission and fusion, but following dysfunction or damage,
mitochondria can become fragmented which often precedes
neuronal cell death (27). To examine the impact of
ATP13A2 overexpression on mitochondrial integrity,
primary cortical neurons were co-transfected with V5-tagged
Figure 6. Silencing of ATP13A2 expression regulates the kinetics of intracellular pH in neurons. (A) Rat primary cortical neurons were co-transfected with
V5-tagged human ATP13A2 (or control empty vector) and EGFP plasmids at a 10:1 molar ratio at DIV 9 to label transfected neurons. At DIV 12, neurons
were loaded with SNARF-1 fluorescent dye to monitor the intracellular pH of individual EGFP-positive neurons by time-lapse, live-cell confocal microscopy.
Following time-lapse imaging of baseline pH over a 120 s period, neurons were exposed to 1 mM cadmium and EGFP-positive neurons were imaged over a 360 s
period. Representative images of EGFP-positive neurons loaded with SNARF-1 dye are shown in the left image, and pseudo-color encoded mosaics indicating
basal (top row) and progressive cadmium-induced acidification (bottom rows) with time are shown in the right image. Warmer tones indicate acidic pH as indi-
cated by lower color scale bar. Scale bar: 50 mm. (B) Average time course of intracellular pH induced by acute cadmium exposure fitted to a first-order kinetic
model (AR3). Cadmium was added at time point 0 s. (C) Fitted parameters of basal and peak intracellular pH after cadmium exposure (left graph) and the rate of
pH change following cadmium exposure (t1/2 in seconds; right graph) are indicated. (D–F) Similar experiments were conducted on primary cortical neurons
co-transfected with non-silencing control shRNA or ATP13A2-specific shRNA and EGFP plasmids at a 10:1 molar ratio. (D) Representative confocal
images of EGFP-positive cortical neurons loaded with SNARF-1 under basal conditions or induced by acute cadmium exposure. (E) Average time course of
intracellular pH following cadmium treatment (fitted to AR3 model) and (F) basal and peak pH (left) or rate (right) induced by cadmium exposure. Data represent
n ¼ 15 neurons/condition sampled from five independent experiments. ∗∗P , 0.01 compared with control condition assessed by unpaired Student’s t-test.
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human ATP13A2 and mito-DsRed2 constructs at a 10:1 molar
ratio, and the morphology of DsRed2-labeled mitochondria
was assessed in individual neurons by live-cell confocal mi-
croscopy (Fig. 8A–C). The overexpression of ATP13A2
does not influence mitochondrial length under basal conditions
or following cadmium exposure (Fig. 8A and C). Acute expos-
ure of cortical neurons to 1 mM cadmium induces a further
decrease in mitochondrial length monitored over a period of
300 s (Fig. 8B). ATP13A2 overexpression leads to a reduced
rate of mitochondrial fragmentation in response to cadmium
exposure in cortical neurons (Fig. 8B and C). The delayed
mitochondrial fragmentation induced by overexpression of
wild-type ATP13A2 was prevented by introduction of the
disease-associated missense mutation, F182L (Supplementary
Figure 7. Modulation of ATP13A2 expression reduces basal intracellular calcium concentration. (A) Rat primary cortical neurons were co-transfected with
V5-tagged human ATP13A2 (or control empty vector) and DsRed plasmids at a 10:1 molar ratio at DIV 9 to label transfected neurons. At DIV 12, neurons
were loaded with Fluo-4 AM fluorescent dye to monitor the intracellular calcium levels of individual DsRed-positive neurons by time-lapse, live-cell confocal
microscopy. Representative time-lapse series of baseline intracellular calcium levels (over 120 s) and following acute cadmium exposure (over 240 s) in DsRed-
positive neurons. Warmer tones indicate higher intracellular calcium concentrations as indicated by lower color scale bar. (B) ATP13A2 overexpression reduces
the levels of basal and cadmium-induced intracellular calcium in neurons. (C) Time course of average intracellular calcium levels induced by cadmium exposure
(at time 0 s) expressed as increased calcium levels over initial basal levels for each neuron. Data were fitted to a first-order kinetic model, and the mean (D) rate
(half-life, t1/2) and (E) maximum peak calcium levels were determined. (F–J) Similar experiments were conducted on primary cortical neurons co-transfected
with non-silencing control shRNA or ATP13A2-specific shRNA and DsRed plasmids at a 10:1 molar ratio. (F) Representative time-lapse series of baseline and
cadmium-induced intracellular calcium levels. (G) ATP13A2 silencing reduces the levels of basal and cadmium-induced intracellular calcium in neurons. (H)
Time course of intracellular calcium levels induced by cadmium exposure and determination of mean (I) rate and (J) maximum calcium levels. Data represent
n ¼ 15 neurons/condition sampled from five independent experiments. ∗∗P , 0.01 or ∗∗∗P , 0.005 compared with the appropriate control condition as indicated
by lines, or by comparing basal versus cadmium conditions, assessed by unpaired Student’s t-test.
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Material, Fig. S4), a putative loss-of-function homozygous
mutation identified in a Japanese subject with early-onset par-
kinsonism (13). To examine the impact of ATP13A2 silencing
on mitochondrial integrity, primary cortical neurons were
co-transfected with shRNA and mito-DsRed2 constructs at a
10:1 molar ratio as described earlier (Fig. 8D–F). Silencing
of ATP13A2 expression induces a marked decrease in mito-
chondrial length consistent with a fragmented phenotype com-
pared with control shRNA (Fig. 8D and F). ATP13A2
silencing further leads to an increased rate of mitochondrial
fragmentation in response to cadmium exposure in cortical
neurons (Fig. 8E and F). The effect of ATP13A2 silencing
on mitochondrial integrity was also assessed in primary mid-
brain dopaminergic neurons. Midbrain cultures were
co-transfected at DIV 3 with shRNA and mito-GFP constructs
at a 10:1 molar ratio to label transfected neurons, fixed at DIV
7 and immunostained with anti-TH antibody to identify dopa-
minergic neurons (Supplementary Material, Fig. S5).
ATP13A2 silencing promotes the fragmentation of mitochon-
dria in dopaminergic neurons compared with control shRNA
(Supplementary Material, Fig. S5). Together, our data
suggest that silencing of ATP13A2 expression in cortical
Figure 8. Silencing of ATP13A2 expression induces mitochondrial fragmentation in neurons. (A) Rat primary cortical neurons were co-transfected with
V5-tagged human ATP13A2 (or control empty vector) and mito-DsRed2 plasmids at a 10:1 molar ratio at DIV 9 to label transfected neurons. At DIV 12,
mito-DsRed2-labeled mitochondria in individual neurons were monitored by time-lapse, live-cell confocal microscopy. Shown are representative time-lapse
image series of mitochondria at baseline (over 120 s) and following acute cadmium exposure (over 240 s) in neurons. (B) Time course of average mitochondrial
length induced by acute cadmium exposure (at time 0 s) indicating delayed cadmium-induced fragmentation in neurons overexpressing human ATP13A2. Data
were fitted to a second-order kinetic model. (C) ATP13A2 overexpression does not alter mean basal or cadmium-induced (peak) mitochondrial length (left
graph), but increases the half-life (t1/2) of cadmium-induced mitochondrial fragmentation (right graph). (D–F) Similar experiments were conducted on
primary cortical neurons co-transfected with non-silencing control shRNA or ATP13A2-specific shRNA and mito-DsRed2 plasmids at a 10:1 molar ratio.
(D) Representative time-lapse image series of mitochondria at baseline and following cadmium treatment. (E) Time course of average mitochondrial length
induced by cadmium exposure (at time 0 s) and determination of (F) mean basal and cadmium-induced (peak) length or the rate of mitochondrial fragmentation.
ATP13A2 silencing reduces basal and cadmium-induced mitochondrial length (left graph) and reduces the half-life of cadmium-induced fragmentation (right
graph). Data represent n ¼ 15 neurons/condition sampled from five independent experiments. ∗P , 0.05 or ∗∗∗P , 0.005 compared with the appropriate
control condition as indicated by lines, or by comparing basal versus cadmium conditions, assessed by unpaired Student’s t-test.
Human Molecular Genetics, 2012, Vol. 21, No. 8 1735
and dopaminergic neurons promotes basal mitochondrial frag-
mentation and sensitizes to the effects of cadmium exposure,
whereas oppositely, overexpression of ATP13A2 in
cortical neurons delays cadmium-induced mitochondrial
fragmentation.
DISCUSSION
Mutations in the ATP13A2 gene cause KRS and early-onset
parkinsonism (4,6,10–12,28). The normal function of
ATP13A2 and the pathogenic mechanism(s) by which reces-
sive mutations precipitate neurodegeneration are poorly under-
stood. Here, we demonstrate that endogenous ATP13A2 is
enriched in the microsomal fraction from mouse brain, and ex-
ogenous ATP13A2 localizes to intracellular acidic vesicles
within mammalian neurons, particularly lysosomes and endo-
somes, and to a smaller extent autophagosomes. We further
demonstrate that ATP13A2 protein is localized to neuronal
populations of the human cerebral cortex and substantia
nigra where this protein is increased in PD and DLB brains.
The overexpression or silencing of ATP13A2 compromises
the integrity of midbrain dopaminergic neurons, leading to
reduced neurite length but without evidence of overt cell
death. Modulation of ATP13A2 expression in cortical
neurons modestly alters the size and number of LC3-positive
autophagosomes but without an obvious effect on autophagic
activation. Consistent with a potential role in regulating ves-
icular cation transport, we find that silencing of endogenous
ATP13A2 in cortical neurons modulates the kinetics of intra-
cellular pH following cadmium-induced acidification and
reduces intracellular calcium levels. Overexpression of
human ATP13A2 similarly reduces intracellular calcium
levels but without influencing pH. Finally, we show that
silencing of ATP13A2 in neurons induces mitochondrial
fragmentation, whereas ATP13A2 overexpression delays
mitochondrial fragmentation induced by cadmium exposure.
Collectively, our study reveals a number of intriguing pheno-
types owing to loss- or gain-of-function of ATP13A2 and sug-
gests a role for ATP13A2 in regulating vesicular cation
transport and neuronal integrity. Furthermore, our data poten-
tially implicate a role for ATP13A2 in idiopathic PD.
Using a specific polyclonal antibody to ATP13A2, we dem-
onstrate the enrichment of ATP13A2 in the microsomal frac-
tion from mouse brain which contains lysosomes, the Golgi
complex and ER. We further demonstrate the localization of
exogenous ATP13A2 to intracellular vesicular compartments
within cortical neurons, particularly lysosomes, early and
late endosomes, microtubule-associated vesicles and to a
smaller extent autophagosomes. Previous studies examining
exogenous ATP13A2 have demonstrated its localization
largely to lysosomes in mammalian cell lines (6,8,9,18).
Therefore, the function of ATP13A2 may be broader than
first anticipated with a preference for vesicular compartments
that are known to be acidic. This might suggest a role for
ATP13A2 in regulating the acidity of such vesicles, similar
to the vesicular vacuolar-type H+-ATPase, through the
active transport of cations across vesicular membranes in an
ATP-dependent manner. In yeast, an ortholog of ATP13A2
termed Ykp9 is localized to the vacuole where it is implicated
in regulating the transport of heavy metal ions, including
cadmium, nickel, manganese and selenium (16,17). Of note,
however, human ATP13A2 is unable to complement the
phenotype of ykp9 null yeast, indicating a lack of functional
conservation between Ykp9 and ATP13A2 (16). The transport
of heavy metal ions by mammalian ATP13A2 has not yet been
directly demonstrated, and consequently, the cation selectivity
of this transporter is not known. A recent study has shown
that the overexpression of human ATP13A2 regulates
intracellular manganese concentration and protects from
manganese-induced toxicity in mammalian cell lines (18).
Whether or not these effects relate to the direct ATP-driven
transport of manganese ions across membranes by ATP13A2
remains to be determined, and whether ATP13A2 can similar-
ly regulate the homeostasis of other heavy metal ions
is not clear.
In the human brain, we demonstrate the localization of
ATP13A2 to various neuronal populations, including pyram-
idal neurons throughout the cerebral cortex and dopaminergic
neurons of the substantia nigra. Furthermore, we detect
ATP13A2 protein migrating as an 130 kDa species in
extracts of human striatum and medial frontal gyrus. A previ-
ous study has reported the expression of ATP13A2 mRNA
throughout the human and mouse brain where it appears to
adopt a neuronal localization with enrichment in the ventral
midbrain and expression in individual dopaminergic neurons
(6). We can confirm that ATP13A2 protein is similarly loca-
lized to neurons, including nigral dopaminergic neurons,
throughout the mouse (data not shown) and human brain.
We further demonstrate that ATP13A2 protein levels are
increased in surviving substantia nigra dopaminergic neurons
and cortical pyramidal neurons of PD brains compared with
normal control brains. These findings are similar to a previous
study which estimated a 10-fold increase in ATP13A2 mRNA
in individual nigral dopaminergic neurons from PD brains
compared with control brains (6). The smaller increase in
protein levels compared with mRNA levels of ATP13A2 in
PD brains could relate to inefficient translation of mRNA,
reduced mRNA stability or to differences in post-mortem
brain tissue. Nevertheless, these data collectively indicate
that ATP13A2 protein levels are increased in vulnerable
neurons from the substantia nigra, striatum and cerebral
cortex of PD brains. The reason for this increase is unclear,
but could relate to a compensatory neuroprotective response
in neurons exposed to PD and/or DLB pathogenic processes
that potentially correlates with up-regulation of the autop-
hagy–endosomal–lysosomal pathways. We have previously
shown that the autophagosomal marker LC3 is increased in
neurons in vulnerable areas of DLB brains (29). Moreover,
we demonstrate that ATP13A2 protein is commonly detected
in neurons harboring LB pathology and that the levels of cyto-
plasmic ATP13A2 are increased in LB-positive neurons com-
pared with neurons without LBs. While ATP13A2 does not
co-localize with LBs directly, this might suggest a compensa-
tory up-regulation of ATP13A2 or acidic vesicles in response
to LBs. It is unlikely that increased ATP13A2 levels directly
impair neuronal viability since (i) this protein is increased in
‘surviving’ nigral dopaminergic neurons of PD brains, (ii)
the overexpression of ATP13A2 is reported to protect from
neuronal toxicity induced by a-synuclein and manganese
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(16,18) and (iii) loss of function of ATP13A2 due to recessive
mutations induces neurodegeneration (4,6,7), consistent with a
normal role for ATP13A2 in neuronal maintenance and/or
neuroprotection in humans.
In attempting to model the pathogenic effects of recessive,
loss-of-function ATP13A2 mutations in primary midbrain
dopaminergic neurons, we find that silencing of endogenous
ATP13A2 expression reduces neurite outgrowth but without
causing neuronal cell death. This effect is somewhat selective
since silencing of ATP13A2 in primary cortical neurons does
not impair neurite outgrowth or induce cell death. Surprising-
ly, the overexpression of human ATP13A2 also markedly
reduces neurite outgrowth of dopaminergic neurons. There-
fore, it appears that there is a critical range of ATP13A2
levels required for the proper maintenance of dopaminergic
neuronal processes. Conceivably, ATP13A2-mediated cation
transport across vesicular membranes is a tightly regulated
process, and dysregulation of this process could potentially
impact the normal function of acidic vesicles, axonal transport
and the subsequent maintenance of neuronal processes. Recent
studies have shown that the overexpression of ATP13A2
orthologs protects from toxicity induced by mutant
a-synuclein in yeast, worm and cultured primary dopamin-
ergic neuronal models (16). Although we have not been able
to show a detrimental effect of ATP13A2 overexpression on
neuronal viability, we find instead that the integrity of neuron-
al processes is compromised. Therefore, a potential note of
caution is warranted for neuroprotective strategies that seek
to increase ATP13A2 levels or activity in pre-clinical
models of PD. It is interesting to note that the lentiviral-
mediated overexpression of ATP13A2 in cultured dopamin-
ergic neurons appears to cause mild neuronal loss (16).
However, in our hands, using single-cell analysis, we do not
observe obvious neuronal loss or apoptotic cell death. The
functional implications of reduced neurite length induced by
silencing or overexpression of ATP13A2 in dopaminergic
neurons are unclear at present and will await the future devel-
opment and analysis of knockout or knockdown mice. Similar-
ly, the reported protective effects of ATP13A2 overexpression
against a-synuclein-induced toxicity will require confirmation
in animal models of PD (16).
Modulation of ATP13A2 expression in cultured primary
cortical neurons produces a range of intracellular phenotypes.
ATP13A2 appears to modestly influence the number and size
of LC3-positive autophagosomes, but does not appreciably
alter autophagic activation based on the levels of the autopha-
gosomal marker, LC3-II. Similar experiments conducted in
human neural cell lines did not reveal a consistent effect of
modulating ATP13A2 expression on autophagic activation or
flux (data not shown). Instead, in cortical neurons, we
observe a reduction in steady-state total GFP-LC3 levels fol-
lowing ATP13A2 silencing or overexpression which may indi-
cate increased lysosomal turnover. We also demonstrate that
ATP13A2 silencing modestly increases the rate of intracellular
acidification induced by acute cadmium exposure but without
an effect on basal pH. These data may suggest that lysosomes
and related acidic vesicles exhibit less tolerance to alterations
in pH following ATP13A2 silencing, indicating that this
protein may play a selective role in maintaining the homeosta-
sis of H+ ions under conditions of cellular stress. It is not clear
whether vesicular pH is similarly affected by ATP13A2 silen-
cing. Yeast cells lacking ykp9 appear most sensitive to growth
on media containing cadmium when compared with other
heavy metals (17). Our data tend to support a functional con-
nection between ATP13A2 and cadmium, whereas manganese
exposure failed to influence intracellular pH in these assays,
thus preventing a similar functional assessment.
We also find that both silencing and overexpression of
ATP13A2 reduce the basal levels of intracellular calcium
ions, an effect that is maintained following cadmium-induced
calcium release. While these observations do not support a
direct relationship between ATP13A2 and cadmium in these
assays, they instead suggest that ATP13A2 may play a role
in regulating calcium homeostasis. Whether or not this effect
is through direct ATP13A2-mediated transport and sequestra-
tion of calcium ions into acidic vesicles is unclear at present,
but it could also result from a general impairment of cation
homeostasis in neurons which might indirectly influence
calcium storage and/or availability. The ability to release
intracellular calcium induced by cadmium exposure is still
intact in neurons following ATP13A2 silencing, suggesting a
modest but not essential role for ATP13A2 in the sequestration
of calcium into intracellular stores. Such a role for ATP13A2
may potentially relate to an indirect effect on the general ionic
homeostasis of neurons due to the dysregulation of acidic vesi-
cles. ATP13A4, a related member of the P5-type ATPase sub-
family, is localized to the ER where its overexpression in
COS-7 cells increases intracellular calcium levels (25). There-
fore, two P5-type ATPases are potentially involved in calcium
regulation albeit within distinct subcellular locations, i.e.
ATP13A4 in the ER and ATP13A2 in lysosomes and related
acidic vesicles. It will be interesting to determine whether add-
itional P5-type ATPases are also involved in regulating intra-
cellular calcium levels. We further show that ATP13A2
influences mitochondrial morphology potentially as a precur-
sor to mitochondrial damage. Similar to the effects on intracel-
lular calcium, silencing of ATP13A2 expression induces basal
mitochondrial fragmentation and increases the rate of mito-
chondrial fragmentation induced by cadmium exposure. The
overexpression of ATP13A2 did not influence mitochondrial
morphology, but instead delayed cadmium-induced mitochon-
drial fragmentation consistent with a neuroprotective effect in
this paradigm. ATP13A2 harboring an F182L mutation, iden-
tified as a homozygous variant in a Japanese subject with
early-onset parkinsonism (13), failed to similarly delay mito-
chondrial fragmentation, suggesting that this disease variant
causes a loss of function. The effects of modulating
ATP13A2 expression on mitochondrial fragmentation do not
initially appear to correlate with their effects on intracellular
calcium levels and pH. Furthermore, ATP13A2 fails to
co-localize with mitochondria in cortical neurons (data not
shown), suggesting an indirect effect on mitochondria poten-
tially through altered vesicular cation transport and cation
homeostasis.
Our data clearly demonstrate that silencing of ATP13A2 ex-
pression, which is anticipated to model recessive disease, is
consistently detrimental to neurons by manifesting dopamin-
ergic neurite shortening and by altering the regulation of intra-
cellular pH, reducing intracellular calcium levels and inducing
mitochondrial fragmentation in primary cortical neurons.
Human Molecular Genetics, 2012, Vol. 21, No. 8 1737
Therefore, neuronal phenotypes due to ATP13A2 silencing
may provide potential insight into the molecular pathways
underlying neurodegeneration due to recessive ATP13A2
mutations in KRS and early-onset parkinsonism. However,
for reasons that are not yet clear, the overexpression of
human ATP13A2 produces varied phenotypes including dopa-
minergic neurite shortening and reduced intracellular calcium
levels, protection from cadmium-induced mitochondrial frag-
mentation, but no effect on intracellular pH regulation. Thus,
ATP13A2 overexpression appears to produce both detrimental
and protective effects on neurons, depending on the specific
phenotype assessed. It will be important to determine in
future experiments whether or not ATP13A2 overexpression
produces an overall beneficial neuroprotective effect in cul-
tures and in vivo, consistent with previous studies reporting
a protective effect against cytotoxicity induced by a-synuclein
overexpression and manganese exposure (16,18). Collectively,
our data support a role for ATP13A2 in the maintenance of
neuronal integrity and the regulation of intracellular cation
homeostasis, autophagy and mitochondrial health. These
broad cellular and subcellular effects may relate to the local-
ization of ATP13A2 to intracellular vesicular compartments
within neurons. Silencing of ATP13A2 in primary neurons
may provide a useful model for understanding the normal
function of this protein and for elucidating the molecular
mechanisms underlying neurodegeneration due to recessive
ATP13A2 mutations.
MATERIALS AND METHODS
Animals
Rats and mice were housed and treated in strict accordance
with the Swiss Legislation (Canton de Vaud, Animal Au-
thorization No. 2293) and the European Community
Council directive (2010/63/EU) for the care and use of la-
boratory animals. Animals were maintained in a pathogen-
free barrier facility and exposed to a 12 h light/dark cycle
with food and water provided ad libitum. Pregnant female
Sprague-Dawley rats were obtained from Charles River La-
boratories (L’Arbresle Cedex, France), and resulting P0 rats
were used for the preparation of post-natal primary neuronal
cultures.
Expression plasmids, antibodies and reagents
A mammalian expression plasmid containing full-length
V5-tagged human ATP13A2 was kindly provided by Dr Chris-
tian Kubisch (University of Cologne, Germany) (6). A
disease-associated missense mutation (F182L) was introduced
into V5-tagged ATP13A2 by site-directed mutagenesis using
the Stratagene QuickChange II XL kit (Agilent Technologies,
La Jolla, CA, USA), according to manufacturer’s instructions.
The integrity of this construct was confirmed by DNA se-
quence analysis. A plasmid containing full-length untagged
mouse ATP13A2 in pCMV-SPORT6 was obtained from
Open Biosystems (Huntsville, AL, USA). Mouse
ATP13A2-EGFP was generated by polymerase chain reaction
from plasmid pCMV-SPORT6-mATP13A2 using forward
(5′-TACTCGAGGCGAGGAGCCGAAATGAGCGC-3′) and
reverse (5′-TAACCGGTCCCCTCACGGAGCCAACGGG
CA-3′) primers and cloned in-frame into 5′ XhoI and 3′ AgeI
sites of plasmid pEGFP-N1 (Clontech, Mountain View, CA,
USA). Mir-30-adapted shRNA sequences in retroviral
plasmid pSM2c targeting rodent ATP13A2 (sh-ATP13A2,
V2MM_84755) or a non-silencing control (sh-control,
V2MM_84756) were obtained from Open Biosystems. GIPZ
lentiviral plasmids co-expressing mir-30-adapted shRNAs tar-
geting rodent ATP13A2 (sh-ATP13A2 #1, V2LMM_84755;
sh-ATP13A2 #2, V3LMM_461110) or a non-silencing
control (sh-control, V3LMM_461109) and turbo GFP were
obtained from Open Biosystems. As plasmid controls, a
pEGFP-N1 plasmid was obtained from Clontech, a
pDsRed-Max-N1 plasmid was from Addgene [plasmid no.
21718, Cambridge, MA, (30)] and a pcDNA3.1 plasmid was
obtained from Invitrogen (Basel, Switzerland). Expression
plasmids containing human GFP-LC3B [plasmid no. 11546,
(31)], human RFP-Rab5A [plasmid no. 14437, (32)], human
GFP-Rab7A [plasmid no. 12605, (33)] and rat LAMP1-RFP
[plasmid no. 1817, (34)] were obtained from Addgene.
Mito-DsRed2, mito-GFP and mito-RFP plasmids were
kindly provided by Dr Manuel Rojo (Universite´ Victor
Segalen, France). The following antibodies were employed:
mouse monoclonal anti-MAP2 (clone HM-2), anti-TH (clone
TH-2) and anti-b-tubulin (clone TUB 2.1) and rabbit poly-
clonal anti-ATP13A2 (A3361, human residues 804–821 and
A9762, human residues 1162–1180), anti-MAP2,
anti-bIII-tubulin and anti-b-actin (Sigma-Aldrich, Buchs,
Switzerland); mouse monoclonal anti-synaptophysin 1 (Syn-
aptic Systems, Go¨ttingen, Germany); mouse monoclonal
anti-LAMP1 (clone LY1C6; EMD Millipore, Billerica, MA,
USA); rabbit polyclonal anti-Giantin (ab24586; Abcam, Cam-
bridge, UK); rabbit monoclonal anti-PDI (clone C81H6; Cell
Signaling Technology, Danvers, MA, USA); mouse monoclo-
nal anti-TIM23 (clone 32; BD Biosciences, Allschwil, Switz-
erland); mouse monoclonal anti-phospho-Ser129-a-synuclein
(Wako Chemicals GmbH, Neuss, Germany); peroxidase-
coupled anti-mouse and anti-rabbit IgG, light chain-specific
secondary antibodies (Jackson ImmunoResearch, Inc., West
Grove, PA, USA) and anti-rabbit IgG and anti-mouse IgG
coupled to AlexaFluor-488, -546 and -633 (Invitrogen).
Fluo-4 AM and SNARF-1 AM fluorescent indicators were
obtained from Invitrogen. Cadmium chloride (CdCl2) and
manganese chloride (MnCl2) were obtained from Sigma.
Generation of ATP13A2 antibodies
A synthetic peptide (CLRINLGGKLQLV) corresponding to
residues 499–511 of human ATP13A2 was used for antibody
generation. This peptide sequence shares high conservation
with rat and mouse ATP13A2. An N-terminal cysteine
residue (underlined) was added to facilitate conjugation to
keyhole limpet hemocyanin. Immunization of rabbits and af-
finity purification of antibodies on columns containing
peptide-immobilized Sulfolink gel matrix (Pierce Biotechnol-
ogy, Rockford, IL, USA) were performed as described
previously (35–37).
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Cell culture and transient transfection
HEK-293T cells were maintained in Dulbecco’s modified
Eagle’s medium (Invitrogen), supplemented with 10% fetal
bovine serum and 1× penicillin/streptomycin at 378C in a
5% CO2 atmosphere. Cells were transfected with plasmid
DNAs using FuGENE HD reagent (Roche Applied Sciences,
Basel, Switzerland), according to manufacturer’s recommen-
dations. For biochemical assays, cells were routinely harvested
at 48–72 h post-transfection.
Primary neuronal cultures and transfection
Primary cortical and midbrain neurons were prepared from
rats, as described previously (38). Whole brains were dissected
from Sprague-Dawley P0 rats, and the cerebral cortices and
ventral midbrain (containing the substantia nigra and ventral
tegmental area) were isolated stereoscopically and dissociated
by digestion in media containing papain (20 U/ml;
Sigma-Aldrich) and mechanical trituration. Cells were plated
in 35 mM dishes onto 10 mM glass cover slips or in 35 mM
IBIDI micro-dishes coated with poly-D-lysine (20 ng/ml; BD
Biosciences) and mouse laminin (33 mg/ml; Invitrogen) and
cultured in Neurobasal media containing B27 supplement
(2% w/v), L-glutamine (500 mM) and penicillin/streptomycin
(100 U/ml) (Invitrogen). At DIV 3, cortical and midbrain cul-
tures were treated with cytosine b-arabinofuranoside (AraC,
10 mM) to inhibit glial cell division. Primary cortical or mid-
brain neurons were transfected with plasmid DNAs using
Lipofectamine 2000 reagent (Invitrogen), according to manu-
facturer’s instructions to a maximum of 5 mg total DNA per
35 mM dish of cells. Cultures were normally maintained up
to DIV 12 without replacement of growth media.
Immunocytochemistry and confocal microscopy
on primary neurons
For co-localization of ATP13A2 and subcellular markers,
primary cortical cultures transiently co-expressing human
ATP13A2-V5 and GFP-LC3, RFP-Rab5A, GFP-Rab7A or
LAMP1-RFP fusion proteins were fixed in 4% paraformalde-
hyde (PFA) containing 4% sucrose in phosphate-buffered
saline (PBS), permeabilized with 0.3% Triton X-100 and se-
quentially incubated with mouse anti-V5 antibody (Invitrogen)
and either rabbit anti-MAP2 (Sigma) or anti-bIII-tubulin
(Sigma) antibodies. Cortical neurons expressing mouse
ATP13A2-GFP were processed for immunocytochemistry
with rabbit anti-ATP13A2 (LMNR1), mouse anti-MAP2
(Sigma) or mouse anti-synaptophysin 1 (Synaptic Systems).
After washing, sections were incubated with the appropriate
AlexaFluor-conjugated secondary antibodies (Invitrogen) and
mounted on glass slides with Vectashield mounting medium
containing DAPI (Vector Laboratories, Burlingame, CA).
Fluorescent images were acquired using a Zeiss LSM 700
inverted confocal microscope (Carl Zeiss AG, Feldbach,
Switzerland) with a Plan-Apochromat 63×/1.40 oil objective
in x-, y- and z-planes. Image analysis was performed using
Fiji software (Image Processing and Analysis in Java) or
Imaris software (Bitplane AG, Zurich, Switzerland). Images
were subjected to deconvolution using HuygensPro software
(Scientific Volume Imaging, Hilversum, The Netherlands).
Pearson’s correlation coefficients (Rcoloc) were calculated
in Fiji using z-stacks between the indicated fluorescent chan-
nels. Representative images are taken from a single z-plane
at a thickness of 0.1 mm.
Cell fractionation and western blotting
For western blotting, HEK-293T cells maintained in growth
medium in six well plates (250 000 cells/well) were transiently
transfected with 2 mg of each plasmid DNA. After 48 h, cells
were harvested in media, resuspended in lysis buffer [1× PBS
pH 7.4, 1% Triton X-100, Complete Mini protease inhibitor
cocktail (Roche Applied Sciences)] and rotated at 48C for
1 h. Lysates were centrifuged at 17 500g for 10 min at 48C,
and the resulting supernatant (Triton-soluble) fraction was col-
lected. Triton-soluble fractions were combined 1:1 with 2×
Laemmli sample buffer (Bio-Rad AG, Reinach, Switzerland)
containing 5% 2-mercaptoethanol and resolved by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE) (7.5%), transferred to Protran nitrocellulose (0.2 mm;
Perkin Elmer, Schwerzenbach, Switzerland) and subjected to
western blot analysis. Nitrocellulose membranes were
probed with anti-ATP13A2 antibody (LMNR1), anti-b-tubulin
or anti-b-actin antibodies (Sigma-Aldrich) and peroxidase-
coupled anti-mouse or anti-rabbit IgG (Jackson ImmunoRe-
search) antibodies. Proteins were visualized by enhanced
chemiluminescence (GE Healthcare, Glattbrugg, Switzerland)
on a FujiFilm LAS-4000 Luminescent Image Analysis system.
Quantitation of protein levels by densitometry was conducted
on acquired images using LabImage 1D software (Kapelan
Bio-Imaging Solutions, Leipzig, Germany).
Human brain tissue
Post-mortem human brain tissue was obtained through the
brain donation program of the Morris K. Udall Parkinson’s
Disease Research Center of Excellence at Johns Hopkins
Medical Institutions in compliance with local Institutional
Review Board and Health Insurance Portability and Account-
ability Act regulations. Fresh-frozen putamen or medial
frontal gyrus tissue from four normal control brains and five
PD/DLB brains was utilized for western blot analysis.
Formalin-fixed, paraffin-embedded tissue sections (10 mm
thick) containing midbrain or cingulate cortex tissue from
three normal control brains and six PD/DLB brains were
used for immunohistochemistry. Table 1 shows the clinical
details of human subjects used in this study.
Fractionation of brain tissue
Detergent-soluble protein fractions were prepared from human
brain tissue (putamen and medial frontal gyrus) or whole
mouse brain by homogenization of samples in TNE buffer
[10 mM Tris–HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5%
NP-40, 1× Complete protease inhibitor cocktail (Roche)].
The homogenate was centrifuged at 100 000g for 20 min at
48C, and the resulting supernatant fraction was collected.
Protein fractions were quantitated using the bicinchoninic
acid (BCA) kit (Pierce Biotechnology) with bovine serum
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albumin standards. Proteins (20–30 mg/lane) were resolved by
SDS–PAGE and analyzed by western blotting with anti-
ATP13A2 (LMNR1) and anti-b-actin antibodies. For antibody
pre-absorption controls, ATP13A2 antibody (LMNR1) was
pre-incubated with an excess of peptide antigen (200 mg/ml)
in Tris-buffered saline overnight at 48C prior to western blot
analysis of mouse brain extracts.
Subcellular fractionation of brain tissue
Subcellular fractionation was conducted as described previ-
ously (35,39) using whole brain tissue from adult C57BL/6J
mice. Briefly, mouse brain homogenates were subjected to
centrifugation at 800g for 10 min to generate pellet (P1,
nuclear/whole cell) and soluble (S1, cytosolic) fractions.
S1 fractions were centrifuged at 9200g for 15 min to
produce P2 (heavy and crude synaptosomal membranes)
and S2 (soluble cytosolic) fractions. The P2 fraction was
solubilized and centrifuged at 25 000g for 20 min to
produce LP1 (synaptosomal membranes) and LS1 (synapto-
somal cytosolic) fractions. The LS1 fraction was further
fractionated by ultracentrifugation at 165 000g for 2 h to
produce LP2 (synaptic vesicle-enriched) and LS2 (synaptic
vesicle cytosolic) fractions. The S2 fraction was subjected
to ultracentrifugation at 165 000g for 2 h to produce P3
(light membranes/microsomes) and S3 (soluble cytosolic)
fractions. Protein concentrations were determined by BCA
assay (Pierce Biotechnology), and equal quantities of each
fraction were validated by western blotting with specific
antibodies labeling mitochondria (TIM23; S1, P2 and
LP1), ER (PDI; P2, P3, LP1 and LP2), Golgi complex
(Giantin; P2 and P3), synaptosomes/synaptic vesicles
(synaptophysin 1; P2, P3, LP1 and LP2) and lysosome
(LAMP1; P3 and S3) subcellular compartments, in addition
to ATP13A2 (LMNR1 antibody).
Immunohistochemistry and immunofluorescence
on human brains
Human midbrain and cingulate cortex tissue sections were
subjected to paraffin removal at 608C for 30 min, xylene treat-
ment and rehydration through a graded ethanol series. Antigen
unmasking was performed by heating at 1008C for 20 min in
10 mM sodium citrate buffer pH 6.0. DAB immunohistochem-
istry was performed on all sections using rabbit anti-ATP13A2
antibodies (LMNR1, A9762/Sigma or A3361/Sigma). Sec-
tions were counterstained with Nissl and dopaminergic
neurons were identified by neuromelanin content, whereas cor-
tical layers were identified by characteristic laminar cytoarchi-
tecture. Slides were imaged on an Olympus AX70 motorized
microscope using a UPLAN FL 4×/0.13 or 20×/0.5 object-
ive, and mosaic images comprising the substantia nigra and
cortex were assembled for three PD and three control cases
(for LMNR1 antibody only), comprising 1257 and 1449
neurons, respectively. The intensity of DAB immunostaining
within these neurons was subjected to semi-quantitative mor-
phometric analysis using NIH ImageJ software as described
previously (29,40) and expressed in arbitrary units. For the
cortex, at least two different areas separated by at least
5 mM were analyzed. For the co-localization analysis of
ATP13A2 with LBs, following antigen unmasking, the
sections were sequentially incubated with rabbit anti-
ATP13A2 antibody (LMNR1) and mouse anti-phospho-
Ser129-a-synuclein (Wako Chemicals) antibody. High
resolution z-stacks were acquired on a Leica SP2 confocal
microscope and were subjected to deconvolution with Huy-
gensPro software. Six distinct regions of cingulate cortex
were analyzed from a single DLB subject (no. 8), encompass-
ing 2179 ATP13A2-positive neurons and 2630 LBs. All image
processing was performed in ImageJ, and data were statistical-
ly post-processed in R software.
Neurite length assays
Primary midbrain cultures at DIV 3 were co-transfected with
V5-tagged human ATP13A2 (or control empty vector) or
mir-30-adapted shRNAs (sh-control or sh-ATP13A2 in retro-
viral vector pSM2c) and EGFP plasmids at a 10:1 DNA
molar ratio to mark transfected neurons. At DIV 7, cultures
were fixed with 4% PFA and subjected to immunocytochem-
istry with mouse anti-TH antibody (Sigma-Aldrich) and anti-
mouse IgG-AlexaFluor-546 antibody (Invitrogen). Fluorescent
images were acquired using an EVOS inverted fluorescence
digital microscope (Advanced Microscopy Group, Bothell,
WA, USA) with a 10× objective. Images were assembled in
ImageJ using a 2D/3D Stitching plugin developed by
Stephan Preibisch (Max Planck Institute of Molecular Cell
Biology and Genetics, Dresden, Germany) to construct the
entire neuritic tree of each EGFP+/TH+ neuron. The length
of EGFP+/TH+ dopaminergic neurites was measured using
the line tool function of ImageJ by an investigator blinded
to each condition. Only neurons that had extended neurites
were measured, whereas neurons without processes were
Table 1. Clinical details of human brain tissue
Subject Diagnosis Brain region PMD
(h)
Age
(years)
Use
1 Normal/control PUT, MFG 12 66 WB
2 Normal/control PUT, MFG 4 74 WB
3 Normal/control PUT, MFG,
CING, MB
8 91 WB, IHC
4 Normal/control PUT, MFG 16 79 WB
5 Normal/control MB 8 80 IHC
6 Normal/control CING, MB 12 48 IHC
1 PD/DLB PUT, MFG 16 86 WB
2 PD/DLB PUT, MFG 19.5 88 WB
3 PD/dementia PUT, MFG 6 75 WB
4 PD/dementia PUT, MFG 17 76 WB
5 PD/dementia PUT, MFG 24 71 WB
6 PD CING 12 45 IHC
7 PD/AD/LB variant CING 18 73 IHC
8 DLB/AD CING 7 89 IHC
9 PD MB 22 71 IHC
10 PD CING, MB 36 77 IHC
11 PD/AD/DLB CING 24 63 IHC
AD, Alzheimer’s disease; CING, cingulate cortex; IHC,
immunohistochemistry; MB, midbrain; MFG, medial frontal gyrus; PMD,
post-mortem delay; PUT, putamen; WB, western blot.
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excluded from the analysis. The longest EGFP+ neurite (i.e.
the axon) was measured and used for comparison among
groups. We measured neurites from every EGFP+/TH+
dopaminergic neuron identified across five cover slips per ex-
periment from at least four independent cultures (n ¼ 39–42
neurons for shRNAs, or n ¼ 28–39 neurons for hATP13A2/
empty vector). For primary cortical neurons, cultures at DIV
3 were transfected with GIPZ constructs co-expressing mir-
30-adapted shRNAs and turbo-EGFP (sh-control,
sh-ATP13A2 #1 or sh-ATP13A2 #2) or with control empty
vector and EGFP plasmids at a 10:1 molar ratio. Cortical
neurons were fixed at DIV 7 and subjected to immunocyto-
chemistry with mouse anti-MAP2 antibody (Sigma-Aldrich)
and anti-mouse IgG-AlexaFluor-633 antibody (Invitrogen).
Fluorescent images were acquired, and EGFP+/MAP+
merged images were pseudo-colored using ICA1 in ImageJ
to improve the contrast of neuritic processes and used for
neurite length measurements. The length of EGFP+/
MAP2+ cortical neurites was determined using ImageJ as
described earlier. In each experiment, neuronal processes
from cortical neurons randomly sampled across five cover
slips from three independent cultures were measured
(n ¼ 111–128 neurons/condition).
TUNEL labeling
Primary cortical neurons at DIV 3 were transfected with
GIPZ-shRNA-EGFP constructs (sh-control, sh-ATP13A2 #1
or sh-ATP13A2 #2) and fixed with 4% PFA at DIV
7. TUNEL staining was conducted using the In Situ Cell
Death Detection Kit (Roche Applied Sciences) containing tet-
ramethylrhodamine red-labeled dUTP as per the manufac-
turer’s instructions. Cultures were further subjected to
immunocytochemistry with mouse anti-MAP2 antibody
(Sigma-Aldrich) and anti-mouse IgG-AlexaFluor-633 anti-
body (Invitrogen). Fluorescent microscopic images were
acquired of double-positive (GFP+/MAP2+) cortical
neurons, and the proportion of TUNEL-positive nuclei was
scored. In each experiment, the number of TUNEL-positive
nuclei from GFP+/MAP+ neurons (n ¼ 199–222/condition)
randomly sampled across two cover slips from three independ-
ent experiments was measured. Data represent TUNEL-
positive neurons as a percent of total GFP+/MAP2+
neurons (mean+SEM) for each condition.
Primary midbrain cultures at DIV 3 were co-transfected
with shRNAs (sh-control or sh-ATP13A2 in vector pSM2c)
and EGFP plasmids at a 10:1 DNA molar ratio to mark trans-
fected neurons. At DIV 7, cultures were fixed with 4% PFA
and subjected sequentially to TUNEL staining as described
earlier and immunocytochemistry with mouse anti-TH anti-
body (Sigma-Aldrich) and anti-mouse IgG-AlexaFluor-633
antibody (Invitrogen). Fluorescent microscopic images were
acquired of double-positive (GFP+/TH+) dopaminergic
neurons, and the proportion of TUNEL-positive nuclei was
scored. In each experiment, the number of TUNEL-positive
nuclei from GFP+/TH+ neurons (n ¼ 15–18/condition) ran-
domly sampled across three cover slips from two independent
experiments was measured.
Analysis of intracellular pH
Live-cell imaging was performed on a Leica SP2 laser scanning
confocal microscope equipped with a CO2 environmental
chamber and temperature control. Primary cortical neuronal cul-
tures seeded on IBIDI micro-dishes were co-transfected at DIV
9with V5-tagged human ATP13A2 (or control empty vector) or
shRNAs (sh-control or sh-ATP13A2) and EGFP at a 10:1 DNA
molar ratio to mark transfected neurons. At DIV 12, neurons
were incubated with 1 mM SNARF-1 AM for 20–30 min in
media without Phenol red. Imaging was performed on
EGFP+ neurons. SNARF-1 was excited with the 561 nm
HeNe laser line and simultaneously recorded at 590/10 and
650/20 nm. Time-lapse high-resolution confocal z-stacks were
acquired, and the F590/F650 ratio was computed for each
voxel. A baseline of 120 s was acquired for each neuron prior
to treatment with 1 mM cadmium and imaging for a further
360 s. Intracellular pH was calculated using the equation
pH ¼ pKa × log10(R2RB/RA2R) × FB590/FA650, where R
is the ratio of fluorescence intensities after subtracting the back-
ground, the subscripts A and B the limiting values at acidic and
basic endpoints (RA ¼ 2.4 andRB¼ 0.05), pKa the experimental
acid dissociation constant (3.16 × 1028) and FB590/FA650 the
ratio of fluorescence at 650 nm in basic and acid endpoints (0.8).
In situ calibration was performed with the potassium ionophore
nigericin (10 mM). Neuronsweremanually segmented into cyto-
solic soma, nucleus and neurites. Average intracellular pH was
calculated for each area.
Intracellular calcium levels
Primary cortical neurons seeded on IBIDI micro-dishes were
co-transfected at DIV 9 with V5-tagged human ATP13A2
(or control empty vector) or shRNAs (sh-control or
sh-ATP13A2) and DsRed plasmids at a 10:1 DNA molar
ratio to mark transfected neurons. At DIV 12, neurons were
incubated with 1 mM Fluo-4 AM for 20–30 min in media
without Phenol red. Imaging was performed on DsRed+
neurons. Fluo-4 was excited with the 488 nm Argon laser
line and recorded at 510/10 nm. Time-lapse high-resolution
confocal z-stacks were acquired for each neuron and were
manually segmented into cytosolic soma, nucleus and neurites.
Average intracellular Fluo-4 fluorescence was calculated for
each area, and data were expressed as raw fluorescence
values. A baseline of 120 s was acquired for each DsRed+
neuron prior to treatment with 1 mM cadmium and imaging
for a further 240 s.
Mitochondrial morphology
Primary cortical neurons seeded on IBIDI micro-dishes were
co-transfected at DIV 9 with V5-tagged human ATP13A2
(or control empty vector) or shRNAs (sh-control or
sh-ATP13A2) and mito-DsRed2 plasmids at a 10:1 DNA
molar ratio to mark transfected neurons. Mito-DsRed2+
neurons were imaged at DIV 12 with a Leica SP2 inverted
confocal microscope. A baseline of 120 s was acquired for
each neuron prior to treatment with 1 mM cadmium and
imaging for a further 240 s. Time-lapse high-resolution con-
focal z-stacks were subjected to deconvolution with
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HuygensPro software, and 3D image reconstruction was con-
ducted using ImageJ. Three-dimensional morphometry mea-
sures (area, ellipticity, sphericity and volume) were
conducted with a 3D Object Counter plugin for ImageJ devel-
oped by Fabrice Cordelieres (Institut Curie, Orsay, France)
and Jonathan Jackson (UCL Institute of Neurology, London,
UK).
Mitochondrial fragmentation in dopaminergic neurons
Primary midbrain neurons at DIV 3 were co-transfected with
shRNAs (sh-control or sh-ATP13A2 in vector pSM2c) and
mito-GFP plasmids at a 10:1 DNA molar ratio to mark trans-
fected neurons. At DIV 7, cultures were fixed with 4% PFA
and subjected to immunocytochemistry with mouse anti-TH
antibody (Sigma-Aldrich) and anti-mouse IgG-AlexaFluor-546
antibody (Invitrogen). Confocal microscopic analysis was con-
ducted on a Zeiss LSM 700 inverted confocal microscope (Carl
Zeiss AG) with a Plan-Apochromat 63×/1.40 oil objective in
x-, y- and z-planes. Mitochondrial morphology was assessed in
individual GFP+/TH+ dopaminergic neurons using
mito-GFP fluorescence. Mitochondria were classified as
tubular (normal), intermediate (partially fragmented plus
tubular network) or fragmented (fully fragmented without
tubular network), according to previously reported criteria
(41).Mitochondrial morphologywas scored from dopaminergic
neurons expressing shRNA/mito-GFP (n ¼ 24–27) sampled
from five cover slips from two independent cultures. Mitochon-
drial morphological subclasses were expressed as a percent of
the total number of mitochondria for each condition.
Autophagosome morphology analysis
Primary cortical neurons were co-transfected at DIV 9 with
V5-tagged human ATP13A2 (or control empty vector) or
shRNAs (sh-control or sh-ATP13A2) and EGFP-LC3 plas-
mids at a 10:1 DNA molar ratio to mark transfected
neurons. At DIV 12, high-resolution confocal z-stacks were
acquired for EGFP-LC3+ neurons. Confocal stacks were sub-
jected to deconvolution with HuygensPro software. The size
and number of EGFP-LC3+ puncta were quantified from
3D stacks using ImageJ.
Statistical analysis
All quantified experiments correspond to at least three inde-
pendent primary cultures. Data are plotted as mean+SEM.
For comparison between conditions, two-tailed unpaired Stu-
dent’s t-test was used, and P , 0.05 was considered signifi-
cant. Statistical analyses were performed with R software
using the CRAN public library for population distribution,
non-lineal fittings and kinetics (The R Project for Statistical
Computing; http://www.r-project.org).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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